GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor)
November 01, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
Considered the equivalent of the Nobel Prize in biopharmaceutical research, Prix Galien USA honors Oxbryta as the Best Biotechnology Product for 2021 Oxbryta is the first and only approved therapy...
GBT Reports Recent Business Progress and Third Quarter 2020 Financial Results
November 05, 2020 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $36.9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months of 2020 ...
GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for Development of Oxbryta® (voxelotor) Tablets
October 12, 2020 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Award® for Industry Innovation...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline – ALKS
February 21, 2019 17:16 ET
|
Pomerantz LLP
NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc. (“Alkermes” or the “Company”) (NASDAQ: ALKS) and certain of its...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline – ALKS
February 14, 2019 15:23 ET
|
Pomerantz LLP
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc. (“Alkermes” or the “Company”) (NASDAQ: ALKS) and certain of its...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline – ALKS
February 07, 2019 16:52 ET
|
Pomerantz LLP
NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc. (“Alkermes” or the “Company”) (NASDAQ: ALKS) and certain of its...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm
February 04, 2019 15:27 ET
|
Faruqi & Faruqi LLP
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the...
Pomerantz Law Firm Announces the Filing of a Class Action against Alkermes plc. and Certain Officers – ALKS
January 31, 2019 20:02 ET
|
Pomerantz LLP
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc. (“Alkermes” or the “Company”) (NASDAQ: ALKS) and certain of its...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm
January 31, 2019 14:31 ET
|
Faruqi & Faruqi LLP
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm
January 14, 2019 16:57 ET
|
Faruqi & Faruqi LLP
NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the...